Acute promyelocytic leukemia: where did we start, where are we now, and the future CC Coombs, M Tavakkoli, MS Tallman Blood Cancer Journal 5 (2015), e304, 2015 | 321 | 2015 |
WUSCHEL mediates stem cell homeostasis by regulating stem cell number and patterns of cell division and differentiation of stem cell progenitors RK Yadav, M Tavakkoli, GV Reddy Development 137 (21), 3581-3589, 2010 | 148 | 2010 |
CD99 is a therapeutic target on disease stem cells in myeloid malignancies SS Chung, WS Eng, W Hu, M Khalaj, FE Garrett-Bakelman, M Tavakkoli, ... Science translational medicine 9 (374), eaaj2025, 2017 | 147 | 2017 |
A high-resolution gene expression map of the Arabidopsis shoot meristem stem cell niche RK Yadav, M Tavakkoli, M Xie, T Girke, GV Reddy Development 141 (13), 2735-2744, 2014 | 141 | 2014 |
A Novel Paradigm Between Leukocytosis, G-CSF Secretion, Neutrophil-to-Lymphocyte Ratio, Myeloid-Derived Suppressor Cells, and Prognosis in Non-small Cell Lung Cancer M Tavakkoli, C Wilkins, J Mones, M Mauro Frontiers in Thoracic Oncology, 2019 | 69 | 2019 |
Pathogenic microRNA’s in myeloid malignancies M Khalaj, M Tavakkoli, AW Stranahan, CY Park Frontiers in genetics 5, 361, 2014 | 51 | 2014 |
CD99 Is a Therapeutic Target On Disease Stem Cells In Acute Myeloid Leukemia and The Myelodysplastic Syndromes SS Chung, M Tavakkoli, SM Devlin, CY Park Blood 122 (21), 2891-2891, 2013 | 18* | 2013 |
Identification of novel markers for stem-cell niche of Arabidopsis shoot apex P Aggarwal, RK Yadav, GV Reddy Gene Expression Patterns 10 (6), 259-264, 2010 | 18 | 2010 |
2024 Update: Advances in the risk stratification and management of large B‐cell lymphoma M Tavakkoli, SK Barta American Journal of Hematology 98 (11), 1791-1805, 2023 | 14 | 2023 |
Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: a US multisite study N Epperla, RL Welkie, P Torka, G Shouse, R Karmali, L Shea, ... Journal of Hematology & Oncology 16 (1), 49, 2023 | 9 | 2023 |
Do preclinical studies suggest that CD99 is a potential therapeutic target in acute myeloid leukemia and the myelodysplastic syndromes? M Tavakkoli, SS Chung, CY Park Expert Opinion on Therapeutic Targets 22 (5), 381-383, 2018 | 8 | 2018 |
Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer J 5: e304 CC Coombs, M Tavakkoli, MS Tallman | 8 | 2015 |
S1563 Acute Acalculous Cholecystitis During Severe COVID-19 Hospitalizations N Wahid, T Bhardwaj, C Borinsky, M Tavakkoli, D Wan, T Wong Official journal of the American College of Gastroenterology| ACG 115, S794, 2020 | 7 | 2020 |
Cutaneous Ewing sarcoma and Ewing sarcoma of the bone: distinct diseases M Tavakkoli, L Mueller Case Reports in Oncology 11 (3), 729-734, 2018 | 7 | 2018 |
Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study N Epperla, Q Zhao, R Karmali, P Torka, L Shea, TS Oh, ... Blood Advances 7 (17), 5038-5046, 2023 | 6 | 2023 |
Survivorship in adolescents and young adults A Kishtagari, M Tavakkoli, J Park Acta Haematologica 132 (3-4), 383-90, 2014 | 6 | 2014 |
The significance of leukocytosis in malignancies: a novel paradigm between leukocytosis, G-CSF, myeloid-derived suppressor cells and prognosis M Tavakkoli, C Wilkins, JV Mones, MJ Mauro Blood 132, 4944, 2018 | 3 | 2018 |
CD99 Is a Therapeutic Target on Disease Initiating Stem Cells in Acute Myeloid Leukemia and the Myelodysplastic Syndromes SS Chung, M Tavakkoli, VM Klimek, CY Park Blood 124 (21), 2014 | 3 | 2014 |
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study K Annunzio, NS Grover, RL Welkie, P Torka, MP Watkins, ... Blood Advances 7 (22), 6839-6843, 2023 | 2 | 2023 |
Targeting CD99 in T-Cell Neoplasms with Monoclonal Antibodies M Tavakkoli, DH Lee, B Durham, SS Chung, CY Park Blood 126 (23), 2749, 2015 | 2 | 2015 |